How common are injection-site reactions with these medicines?

Injection-site reactions such as redness, hardening (induration) or itching are common with subcutaneous peptide therapies generally and are described in pivotal trials, but the great majority are mild and resolve without intervention. Severe hypersensitivity reactions are uncommon but are recognised as possible in UK product information.

Does rotating the injection site reduce reactions?

Rotating the injection site is standard administration guidance found in patient information leaflets for subcutaneous peptide therapies generally. The specific contribution of site rotation, formulation, device and excipients to individual tolerability has not been separately quantified for this class.

What distinguishes a normal reaction from a hypersensitivity reaction?

Mild, localised redness, swelling or itching that settles within a short period is consistent with the common, self-limiting reactions described in trials. Severe, spreading redness, blistering, or systemic symptoms such as widespread rash, swelling of the face or throat, or breathing difficulty are different in character and should be treated as a reason for urgent review rather than routine site care.

When should an injection-site reaction be reported or reviewed?

Severe redness, swelling, blistering or any systemic symptoms should be flagged to the prescriber promptly rather than managed independently. Reactions of this severity can also be reported through the MHRA Yellow Card scheme.

Injection-site reactions in clinical trials

What is known

Most reactions are mild and resolve without intervention.
Severe hypersensitivity is uncommon but possible.

What remains uncertain

Specific contribution of formulation, device and excipients to individual tolerability.

Trial limitations

Reporting standards vary across trials.

FAQs

How common are injection-site reactions with these medicines?: Injection-site reactions such as redness, hardening (induration) or itching are common with subcutaneous peptide therapies generally and are described in pivotal trials, but the great majority are mild and resolve without intervention. Severe hypersensitivity reactions are uncommon but are recognised as possible in UK product information.
Does rotating the injection site reduce reactions?: Rotating the injection site is standard administration guidance found in patient information leaflets for subcutaneous peptide therapies generally. The specific contribution of site rotation, formulation, device and excipients to individual tolerability has not been separately quantified for this class.
What distinguishes a normal reaction from a hypersensitivity reaction?: Mild, localised redness, swelling or itching that settles within a short period is consistent with the common, self-limiting reactions described in trials. Severe, spreading redness, blistering, or systemic symptoms such as widespread rash, swelling of the face or throat, or breathing difficulty are different in character and should be treated as a reason for urgent review rather than routine site care.
When should an injection-site reaction be reported or reviewed?: Severe redness, swelling, blistering or any systemic symptoms should be flagged to the prescriber promptly rather than managed independently. Reactions of this severity can also be reported through the MHRA Yellow Card scheme.